/ Not yet recruiting临床1期IIT A Phase 1 Trial of Menin-inhibitor Ziftomenib in Combination with Chemotherapy for Children with Relapsed/Refractory KMT2A-r/NUP98-r/NPM1-m Acute Leukemia
The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).
100 项与 LLS PedAL Initiative, LLC 相关的临床结果
0 项与 LLS PedAL Initiative, LLC 相关的专利（医药）
100 项与 LLS PedAL Initiative, LLC 相关的药物交易
100 项与 LLS PedAL Initiative, LLC 相关的转化医学
